

**LISTING OF CLAIMS**

Claims 1-25 (CANCELED) :

- 5      **26. (NEW)** A combination comprising a combination of an antioxidant agent and a mixed PPAR ligand for the  $\alpha$  and  $\gamma$  receptor sub-types, or a selective PPAR ligand for the  $\alpha$  receptor sub-type and a selective PPAR ligand for the  $\gamma$  receptor sub-type.
- 27. (NEW)** The composition of Claim 26, wherein the PPAR ligand is a mixed ligand for the  $\alpha$  and  $\gamma$  receptor sub-types.
- 28. (NEW)** The composition of Claim 26, comprising an antioxidant agent and a selective ligand for the  $\alpha$  receptor sub-type and a selective ligand for the  $\gamma$  receptor sub-type.
- 10      **29. (NEW)** The composition of Claim 26, wherein the selective PPAR ligand for the  $\gamma$  receptor sub-type is rosiglitazone or an addition salt thereof with a pharmaceutically acceptable acid or base.
- 30. (NEW)** The composition of Claim 26, wherein the antioxidant agent is ubiquinone or coenzyme Q<sub>10</sub>.
- 15      **31. (NEW)** A composition comprising a combination of rosiglitazone and coenzyme Q<sub>10</sub>.
- 32. (NEW)** A pharmaceutical composition comprising as active ingredient a composition of Claim 26, in combination with one or more pharmaceutically-acceptable excipients.
- 33. (NEW)** A method for treating and/or preventing a living animal body, including a human, afflicted with obesity comprising the step of administering to the living animal  
20      body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of obesity.

34. (NEW) A method for treating a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of said disorder.
- 5      35. (NEW) A method for treating a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of obesity caused by treatment for type I or II diabetes.
- 10     36. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.
- 15     37. (NEW) A method for treating a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.
- 20     38. (NEW) A method for treating a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.
- 25     39. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity, comprising the step of administering to the living animal

body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity.

5       **40. (NEW)** A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity caused by a therapeutic treatment.

10       **41. (NEW)** A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity caused by treatment for type I or II diabetes.

15       **42. (NEW)** A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more  
20       PPAR ligands and an antioxidant agent which is effective for alleviation of the condition.

25       **43. (NEW)** A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of the condition.

- 5 44. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of the condition..